Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854556 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29401188 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL119488 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29401751 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL2307942 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29516375 | 0.93 | MDM4 (0.53) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL430008 | 0.93 | MDM2 (0.56) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL30861860 | 0.93 | MDM2 (0.56) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL3732565 | 0.93 | MDM2 (0.56) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL3733904 | 0.93 | MDM2 (0.56) | MDM4TP53MDM2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-3773555-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019186164-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9345789-B2 | Specific inhibitors and active site probes for legumain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2007117404-A9 | METHODS AND MATERIALS FOR PREPARING ORGANIC COMPOUNDS FROM PRIMARY AMINES | UNIV VIRGINIA (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007117404-A2 | METHODS AND MATERIALS FOR PREPARING ORGANIC COMPOUNDS FROM PRIMARY AMINES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20030225272-A1 | Novel mmp-2/mmp-9 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-12-04 | — | — | US | disclosed |
| WO-2001026671-A1 | METHODS OF TREATMENT USING DUAL MATRIX-METALLOPROTEINASE-2 AND MATRIX METALLOPROTEINASE-9 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225272-A1 | Novel mmp-2/mmp-9 inhibitors | MMP9, MMP10, MMP3 | MDM4 3210/4885TP53 2656/4885MDM2 1123/4885 |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | MDM4 3892/4885TP53 1996/4885MDM2 1644/4885 |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | MDM4 3892/4885TP53 1996/4885MDM2 1644/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | MDM4 4205/4885TP53 4817/4885MDM2 4846/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | MDM4 4205/4885TP53 4817/4885MDM2 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.